Joaquín Arribas

Overview

Best Publications

• Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

  Maurizio Scaltriti;Federico Rojo;Alberto Ocaña;Judit Anido

  1038
  Citations

• Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells

  Miguel A. Molina;Jordi Codony-Servat;Joan Albanell;Federico Rojo

  1026
  Citations

• NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

  Violeta Serra;Benjamin Markman;Maurizio Scaltriti;Pieter J A Eichhorn

  939
  Citations

• Interrogating open issues in cancer precision medicine with patient-derived xenografts

  Annette T. Byrne;Denis G. Alférez;Frédéric Amant;Daniela Annibali

  630
  Citations

• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

  V. Serra;M. Scaltriti;L. Prudkin;Pieter Eichhorn

  617
  Citations

• Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors

  Joaquin Arribas;Lavanya Coodly;Petra Vollmer;Takashi Kei Kishimoto

  516
  Citations

• Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

  M Scaltriti;C Verma;M Guzman;J Jimenez

  497
  Citations

• Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) Superiority Over Single-Agent Receptor Targeting

  Pablo Matar;Federico Rojo;Raúl Cassia;Gema Moreno-Bueno

  439
  Citations

• Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity

  Monireh Roghani;J. David Becherer;Marcia L. Moss;Ruth E. Atherton

  420
  Citations

• TACE is required for the activation of the EGFR by TGF-α in tumors

  Maria Borrell-Pagès;Federico Rojo;Joan Albanell;Josep Baselga

  353
  Citations

• RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  C. Cruz;M. Castroviejo-Bermejo;S. Gutiérrez-Enríquez;A. Llop-Guevara

  350
  Citations

• Mechanism of action of trastuzumab and scientific update.

  José Baselga;Joan Albanell;Miguel Angel Molina;Joaquin Arribas

  348
  Citations

• Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

  Jordi Codony-Servat;Joan Albanell;Juan Carlos Lopez-Talavera;Joaquín Arribas

  339
  Citations

• Protein Ectodomain Shedding

  Joaquín Arribas;Aldo Borroto

  293
  Citations

• Identification and characterization of Cardiac Glycosides as senolytic compounds

  Francisco Triana-Martínez;Pilar Picallos-Rabina;Sabela Da Silva-Álvarez;Federico Pietrocola

  289
  Citations

• Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.

  Gloria Velasco;Santiago Cal;Anna Merlos-Suárez;Adolfo A. Ferrando

  279
  Citations

• p95HER2 and Breast Cancer

  Joaquín Arribas;José Baselga;Kim Pedersen;Josep Lluís Parra-Palau

  276
  Citations

• Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation

  Judit Anido;Maurizio Scaltriti;Joan Josep Bech Serra;Belén Santiago Josefat

  275
  Citations

• ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

  Judit Anido;Pablo Matar;Joan Albanell;Marta Guzmán

  262
  Citations

• NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, PreventsPI3K Signaling and Inhibitsthe Growth of Cancer Cellswith Activating PI3K Mutations

  Violeta Serra;Ben Markman;Maurizio Scaltriti;Vanesa Valero

  0
  Citations